Jonsson Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Jonsson Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#111 of 15,742 sponsors by registered trial count).
Jonsson Comprehensive Cancer Center: 321 sponsored US clinical trials, 61 recruiting.
Jonsson Comprehensive Cancer Center sponsors 321 registered US clinical trials on ClinicalTrials.gov, 61 of them currently recruiting, and 164 completed. 13 of these trials are in Phase 3-4 (later-stage) and 206 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Carcinoma, with 10 trials.
Top-decile sponsor footprint
Jonsson Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#111 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
164 of 203 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
321 total, page 6 of 7
Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma
NCT00087061
Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer
NCT00096057
Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
NCT00087035
Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors
NCT00091299
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
NCT00088946
CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
NCT00090896
GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu
NCT00085020
Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
NCT00346372
ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma
NCT00081042
BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate
NCT00064233
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
NCT00079222
Increasing Adherence to Follow-up of Breast Abnormalities in Low-Income Korean American Women
NCT00742755
Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00072072
Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse
NCT00071968
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
NCT00070382
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
NCT00068341
Ro 50-3821 in Treating Anemia in Patients Receiving Antineoplastic Therapy for Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00072059
Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
NCT00090909
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery
NCT00049322
Vaccine Therapy in Treating Patients With Malignant Glioma
NCT00068510
Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy
NCT00066508
Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00060294
Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
NCT00062179
CP-724,714 in Treating Patients With Metastatic Breast Cancer
NCT00055926
LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors
NCT00052273
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
NCT00054574
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00049257
Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer
NCT00052286
Sirolimus in Treating Patients With Glioblastoma Multiforme
NCT00047073
Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer
NCT00039273
Exatecan Mesylate in Treating Patients With Advanced Solid Tumors and Kidney Dysfunction
NCT00045318
Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer
NCT00047255
Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma
NCT00039325
Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00040950
Biological Therapy in Treating Patients With Prostate Cancer
NCT00039299
Low-Fat Fish Oil Diet for Prostate Cancer Prevention
NCT00798876
Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia
NCT00020800
Low-Fat, High-Fiber Diet Compared to a Standard Diet in Treating Patients With Prostate Cancer
NCT00020995
Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression
NCT00033514
Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer
NCT00020787
Cryosurgery in Treating Women With Breast Lesions
NCT00020852
STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic Leukemia
NCT00015860
Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers
NCT00020878
Vaccine Therapy in Treating Patients With Liver Cancer
NCT00022334
Temozolomide in Treating Patients With Solid Tumors That Have Spread to the Brain
NCT00012116
CCI-779 in Treating Patients With Prostate Cancer
NCT00012142
Pentostatin Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Kidney Cancer
NCT00006968
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
NCT00024076
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach
NCT00020761
Vaccine Therapy in Treating Patients With Advanced Cancer
NCT00004881
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 106 |
| Phase 2 | 100 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Jonsson Comprehensive Cancer Center pipeline
61 recruiting of 321 indexed (19% open); 164 completed (51%).
Phase mix: 13 late (III/IV) vs 206 early (I/II) (early-phase heavy).
Top condition: Prostate Carcinoma (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Jonsson Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 321 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
Jonsson Comprehensive Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 321 trials (± recruiting share)
- Rush University Medical Center · 320 trials · 17% recruiting
- University of Arkansas · 318 trials · 12% recruiting
- Allergan · 314 trials · 0% recruiting
- Genentech · 332 trials · 7% recruiting
Sponsors near 19% open enrollment (± trial volume)
- MemorialCare Health System · 19% recruiting · 21 trials
- University of North Texas Health Science Center · 19% recruiting · 21 trials
- University of Wisconsin, Milwaukee · 19% recruiting · 21 trials
- Verastem · 19% recruiting · 21 trials
Related
What to do with this Jonsson Comprehensive Cancer Center page
321 registered trials is a research-attention snapshot, not an endorsement of Jonsson Comprehensive Cancer Center or any single study.
- 61 of Jonsson Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Carcinoma is the condition Jonsson Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Jonsson Comprehensive Cancer Center pipeline card: 321 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.